ArticleInternational journal of clinical oncology2016

Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab.

Mutsushi Yamasaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.